Dr Lal PathLabs Reports Robust Q2 FY27 With 27.5% YoY PAT Growth
Dr. Lal PathLabs Ltd 路 Investor Presentation 路 04 Nov 2026, 7:48 pm
Dr Lal PathLabs Reports Robust Q2 FY27 With 27.5% YoY PAT Growth Dr Lal PathLabs delivered strong Q2 FY27 performance, with revenue growing 19.6% YoY to INR 874 Cr, driven by a 13.6% YoY rise in sample volumes (28.8 Mn) and 9.0% YoY patient growth (9.0 Mn). EBITDA rose 25.1% YoY to INR 280 Cr, expanding margins by 140 bps to 32.1%. PAT increased 27.5% YoY to INR 194 Cr. H1 FY27 revenue reached INR 1,672 Cr (+19.4% YoY) with PAT of INR 364 Cr (+27.3% YoY). SwasthFit contributed 26% of Q2 revenue. Cash and equivalents stood at INR 1,746 Cr.
Original exchange filing (PDF)
More announcements from Dr. Lal PathLabs Ltd
- Attached 路 11 Nov 2026
- Attached 路 10 Nov 2026
- Attached 路 05 Nov 2026
- Attached 路 04 Nov 2026
- Attached 路 04 Nov 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Ms Vasuta Agarwal as Additional Director designated as Non- Executive Independent Director of the company w.e.f. November 04, 2026. 路 04 Nov 2026
- Attached 路 04 Nov 2026
- Dr. Lal Path Labs Ltd. has informed the Exchange about General Updates 路 04 Nov 2026
